Studies have also revealed that de novo AML with BCR/ABL1 has more prevalence of fusion protein 190 and NPM1 mutation in contrast to Ph+CML and also possess different treatment and prognostic value than CML with BCR/ABL1 in blast phase.8 Here, NPM1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.